Premium
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab
Author(s) -
Kennedy G. A.,
Seymour J. F.,
Wolf M.,
Januszewicz H.,
Davison J.,
McCormack C.,
Ryan G.,
Prince H. M.
Publication year - 2003
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1034/j.1600-0609.2003.00143.x
Subject(s) - alemtuzumab , medicine , cd52 , mycosis fungoides , gastroenterology , tolerability , chronic lymphocytic leukemia , refractory (planetary science) , leukemia , lymphoma , surgery , adverse effect , transplantation , physics , astrobiology
Objectives: Alemtuzumab (anti‐CD52, Campath‐1H) has recently been shown to be effective in the treatment of a range of hematological malignancies, including B‐cell chronic lymphocytic leukemia and T‐cell prolymphocytic leukemia. We undertook a phase II study to evaluate the safety, tolerability and efficacy of alemtuzumab in patients with relapsed or refractory advanced stage cutaneous T‐cell lymphoma. Patients and methods: A total of eight patients were enrolled, seven with mycosis fungoides/Sézary syndrome (MF/SS) and one with large‐cell transformation of MF. Seven patients had disease refractory to multiple previous therapies. Alemzumab (30 mg) was administered intravenously three times per week for 12 wk or until maximum response. Results: The overall response rate was 38%, with three patients achieving partial remission, two patients with stable disease and three patients with progressive disease (PD) during treatment. The time to progression was short, with all patients developing PD within 4 months of starting alemtuzumab. Response duration in the three PR patients was also brief, with responses lasting less than 3 months in all three cases. Significant hematological and immunosuppressive toxicity was observed, with both grade 3–4 cytopenias and significant infectious complications occurring in a majority of cases. Conclusions: Our findings suggest that in heavily pretreated, refractory, advanced stage MF/SS, although alemtuzumab has biological activity, it is associated with significant toxicity and only modest clinical utility. As such, combination regimens incorporating alemtuzumab merit further investigation in this difficult to treat patient group.